Genetics News and Research

Latest Genetics News and Research

Study finds that disarray in methylation helps tumors adapt to changing circumstances

The genetic tumult within cancerous tumors is more than matched by the disorder in one of the mechanisms for switching cells' genes on and off, scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard report in a new study.

9 Dec 2014

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

CTI BioPharma Corp. today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays.

9 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Triple hormone reduces body weight, improves insulin sensitivity

Recently, the researchers had constructed several single molecules with dual hormone action. Now, for the first time, the researchers succeeded in designing a substance that combines three metabolically active hormone components (GLP-1, GIP and glucagon) and offers unmatched potency to fight metabolic diseases in pre-clinical trials.

9 Dec 2014

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Screening system spots cancerous changes invisible to sequencing

A technique that can identify causes of cancer invisible to genetic sequencing has uncovered large sets of previously unknown pancreatic cancer genes. It is hoped that this study will boost research into a disease that is still poorly understood and for which five-year survival rates have stood at around 5 per cent for the past four decades.

8 Dec 2014

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

8 Dec 2014

Baylor-led researchers identify gene linked to familial glioma

An international consortium of researchers led by Baylor College of Medicine has identified for the first time a gene associated with familial glioma (brain tumors that appear in two or more members of the same family) providing new support that certain people may be genetically predisposed to the disease.

8 Dec 2014

Researchers identify new targets for future CLL therapies

Chronic lymphocytic leukemia (CLL) is among the most frequent leukemias affecting adults in Western countries. It usually occurs in older patients, does not cause any symptoms for a long time and is often only discovered by accident. Despite treatment, relapses frequently occur. The immunologists Dr. Kristina Heinig and Dr. Uta Höpken (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) and the hematologist Dr. Armin Rehm (MDC and Charité - Universitätsmedizin Berlin) have now discovered why this is so.

7 Dec 2014

Scientists devise powerful algorithm to improve effectiveness of research technology harnessing RNAi

Scientists at Cold Spring Harbor Laboratory have devised a powerful algorithm that improves the effectiveness of an important research technology harnessing RNA interference, or RNAi.

7 Dec 2014

Researchers reveal that genetic mutations may cause more cases of ALS

Genetic mutations may cause more cases of amyotrophic lateral sclerosis (ALS) than scientists previously had realized, according to researchers at Washington University School of Medicine in St. Louis and Cedars-Sinai Medical Center in Los Angeles. The scientists also showed that the number of mutated genes influences the age when the fatal paralyzing disorder first appears.

7 Dec 2014

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM).

7 Dec 2014

Genetics may play major role in Lou Gehrig's disease, study reveals

Genetics may play a larger role in causing Lou Gehrig's disease than previously believed, potentially accounting for more than one-third of all cases, according to one of the most comprehensive genetic studies to date of patients who suffer from the condition also known as amyotrophic lateral sclerosis, or ALS.

6 Dec 2014

Researchers suggest new strategy to control cellular identity and fate

A team of scientists that included researchers from UCLA has discovered a novel mechanism of RNA regulation in embryonic stem cells. The findings are strong evidence that a specific chemical modification, or "tag," on RNA plays a key role in determining the ability of embryonic stem cells to adopt different cellular identities.

6 Dec 2014

Researchers identify important neural mechanism responsible for certain chronic pain disorders

Pain typically has a clear cause-but not always. When a person touches something hot or bumps into a sharp object, it's no surprise that it hurts. But for people with certain chronic pain disorders, including fibromyalgia and phantom limb pain, a gentle caress can result in agony.

6 Dec 2014

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT).

5 Dec 2014

Most parents interested in newborn genomic testing, study reveals

A study published this week in Genetics in Medicine is the first to explore new parents' attitudes toward newborn genomic testing. The findings suggest that if newborn genomic testing becomes available, there would be robust interest among new parents, regardless of their demographic background.

5 Dec 2014

Study: PET scanning strategy could help predict effectiveness of TB drugs

Sophisticated lung imaging can show whether or not a treatment drug is able to clear tuberculosis (TB) lung infection in human and macaque studies, according to researchers at the University of Pittsburgh School of Medicine and their international collaborators.

5 Dec 2014

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics, Inc. today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug Discovery for its discovery of ibrutinib (IMBRUVICA). The award was presented by The Society of Medicines Research at its biennial award lecture in Kensington, London.

4 Dec 2014

Genetics News and Research

Latest Genetics News and Research

Study finds that disarray in methylation helps tumors adapt to changing circumstances

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Triple hormone reduces body weight, improves insulin sensitivity

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Screening system spots cancerous changes invisible to sequencing

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Baylor-led researchers identify gene linked to familial glioma

Researchers identify new targets for future CLL therapies

Scientists devise powerful algorithm to improve effectiveness of research technology harnessing RNAi

Researchers reveal that genetic mutations may cause more cases of ALS

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Genetics may play major role in Lou Gehrig's disease, study reveals

Researchers suggest new strategy to control cellular identity and fate

Researchers identify important neural mechanism responsible for certain chronic pain disorders

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Most parents interested in newborn genomic testing, study reveals

Study: PET scanning strategy could help predict effectiveness of TB drugs

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Sequencing & Genomics: Elevating Science and Healthcare eBook

Latest eBooks

Industry Focus eBook - Neurology/Neuroscience - 2nd edition

Industry focus eBook: Genomics (4th edition)

Industry Focus eBook - Clinical & Point of Systems Diagnostics (1st edition)

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition)

How Programmable Nanobiology Could Drive the Fifth Industrial Revolution

Dr. Anthony Grice

Building quality into drug development for safer, faster medicines